Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilbert Youssef

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Neuro-Oncology Advances|February 16, 2026
Evaluation of sex differences in survival among glioblastoma patients treated with immune checkpoint inhibitorsVihang Nakhate, Catharina Westergaard, Zhou Lan, et al.
Neuro-Oncology|June 24, 2024
The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?Martin J van den Bent, Pim J French, Daniel Brat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2023
Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent GlioblastomaGilbert Youssef, Rifaquat Rahman, Camden Bay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2023
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in AdultsPatrick Y Wen, Martin van den Bent, Gilbert Youssef, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 1, 2023
Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse modelsMeenal Datta, Sampurna Chatterjee, Elizabeth M Perez, et al.
Neuro-Oncology|December 15, 2025
Prognostic Significance of MGMT Promoter Methylation Status in IDH-mutant GliomaGilbert Youssef, Elisa Aquilanti, Julie J Miller, et al.
Nature Cancer|June 3, 2026
Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastomaJack Y Ghannam, Julian Bryan, Jakob Weiss, et al.
Neuro-Oncology|May 29, 2025
Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4Aleksandra B Lasica, Zhou Lan, Julie J Miller, et al.
Neuro-Oncology|August 20, 2024
Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumorsHia S Ghosh, Ruchit V Patel, Eleanor Woodward, et al.
Neuro-Oncology Advances|February 6, 2025
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomesTyler A Lanman, Gilbert Youssef, Raymond Huang, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Neuro-Oncology Advances|February 16, 2026
Evaluation of sex differences in survival among glioblastoma patients treated with immune checkpoint inhibitorsVihang Nakhate, Catharina Westergaard, Zhou Lan, et al.
Neuro-Oncology|June 24, 2024
The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?Martin J van den Bent, Pim J French, Daniel Brat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2023
Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent GlioblastomaGilbert Youssef, Rifaquat Rahman, Camden Bay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2023
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in AdultsPatrick Y Wen, Martin van den Bent, Gilbert Youssef, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 1, 2023
Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse modelsMeenal Datta, Sampurna Chatterjee, Elizabeth M Perez, et al.
Neuro-Oncology|December 15, 2025
Prognostic Significance of MGMT Promoter Methylation Status in IDH-mutant GliomaGilbert Youssef, Elisa Aquilanti, Julie J Miller, et al.
Nature Cancer|June 3, 2026
Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastomaJack Y Ghannam, Julian Bryan, Jakob Weiss, et al.
Neuro-Oncology|May 29, 2025
Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4Aleksandra B Lasica, Zhou Lan, Julie J Miller, et al.
Neuro-Oncology|August 20, 2024
Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumorsHia S Ghosh, Ruchit V Patel, Eleanor Woodward, et al.
Neuro-Oncology Advances|February 6, 2025
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomesTyler A Lanman, Gilbert Youssef, Raymond Huang, et al.
Pageof 4